AKERO THEREP.INC.DL-0001 (0K4 F) stock market data APIs
€45.8737
0(0%)
as of October 15, 2025
Try our APIs with
free plan!
AKERO THEREP.INC.DL-0001 Financial Data Overview
Price chart is built with
Anychart
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
45.8737
Open
45.8737
High
45.8737
Low
45.8737
52 wk Range
21.19-55.1
Market Cap
3 704 M
Shares Outstanding
80 165 K
EPS
-0.83
Beta
-0.294
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AKERO THEREP.INC.DL-0001 data using free add-ons & libraries
Get AKERO THEREP.INC.DL-0001 Fundamental Data
AKERO THEREP.INC.DL-0001 Fundamental data includes:
- Net Revenue:
- EBITDA: -321 457 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -0.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AKERO THEREP.INC.DL-0001 News
New
Why Biotech’s Rally Can Last This Time
After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. Whether the run continues will depend on several factors: continued funding, a pre...
Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.
The recent cavalcade of biotech deals continued Friday morning, when Bristol Myers Squibb said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech...
Earnings, Fed Rates Mean Stocks Can Ignore the Shutdown. This Could Change That.
Government shutdown hits day 10, U.S. begins Argentine rescue, Amazon Prime shoppers snapped up necessities, and more news to start your day. Continue Reading View Comments
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger
We recently published 10 Big Names With Whopping Gains; 6 Jump All-Time Highs. Akero Therapeutics, Inc. (NASDAQ:AKRO) is one of the best performers on Thursday. Akero Therapeutics saw its share price...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
